128 related articles for article (PubMed ID: 19349140)
1. [Intestinal perforation: an unusual adverse event of bevacizumab and paclitaxel combined therapy for a metastatic breast cancer].
Mychaluk J; Piprot C; Sevestre H; Merviel P; Gondry J; Fauvet R
Presse Med; 2009 Sep; 38(9):1370-4. PubMed ID: 19349140
[No Abstract] [Full Text] [Related]
2. [Nasal septum perforation and bevacizumab].
Bengrine-Lefevre L; Afchain P; Chibaudel B; Gervais H; Tournigand C; De Gramont A; Louvet C
Rev Med Interne; 2011 Apr; 32(4):e43-5. PubMed ID: 21470582
[TBL] [Abstract][Full Text] [Related]
3. Nasal septum perforation in a bevacizumab-treated patient with metastatic breast cancer.
Traina TA; Norton L; Drucker K; Singh B
Oncologist; 2006; 11(10):1070-1. PubMed ID: 17110625
[No Abstract] [Full Text] [Related]
4. [A complete response following treatment with Paclitaxel and bevacizumab for metastatic breast cancer].
Tsubota Y; Sueoka N; Yamamoto D
Gan To Kagaku Ryoho; 2014 Nov; 41(12):1954-6. PubMed ID: 25731387
[TBL] [Abstract][Full Text] [Related]
5. Herceptin-taxol related hand and foot syndrome.
Merimsky O; Inbar MJ
Isr Med Assoc J; 2000 Oct; 2(10):786. PubMed ID: 11344738
[No Abstract] [Full Text] [Related]
6. Managing adverse events in the use of bevacizumab and chemotherapy.
Blowers E; Hall K
Br J Nurs; 2009 Mar 26-Apr 8; 18(6):351-6, 358. PubMed ID: 19329899
[TBL] [Abstract][Full Text] [Related]
7. Spontaneous nasal perforation in a bevacizumab-treated patient with metastatic breast cancer.
Rodriguez CA; Martin T; Lozano R; Gomez A; Cruz JJ
Breast J; 2017 Nov; 23(6):745-746. PubMed ID: 28845572
[TBL] [Abstract][Full Text] [Related]
8. Bevacizumab-induced intestinal perforation in a patient with inoperable breast cancer: a case report and review of the literature.
Fujii Y; Hirahara N; Kaji S; Taniura T; Hyakudomi R; Yamamoto T; Tajima Y
J Med Case Rep; 2018 Mar; 12(1):84. PubMed ID: 29580267
[TBL] [Abstract][Full Text] [Related]
9. Bevacizumab-induced small bowel perforation in a patient with breast cancer without intraabdominal metastases.
Lecarpentier E; Ouaffi L; Mir O; Berveiller P; Maurel M; Pujade-Lauraine E; Bouillot JL; Veyrie N
Invest New Drugs; 2011 Dec; 29(6):1500-3. PubMed ID: 20676743
[TBL] [Abstract][Full Text] [Related]
10. Grade 4 epistaxis in a woman with metastatic breast cancer treated with bevacizumab: a case report.
Yanagihara K; Takei H; Iida S; Yamashita K; Kurita T; Iwamoto M; Saegusa H; Uchida E
J Nippon Med Sch; 2014; 81(5):333-6. PubMed ID: 25391703
[TBL] [Abstract][Full Text] [Related]
11. Discordant somatic and germline VEGF-A genotype in a cancer patient resistant to paclitaxel/bevacizumab with chemosensitive hepatic metastasis.
Coltelli L; Allegrini G; Orlandi P; Giuntini N; Alì G; Fioravanti A; Bona E; Barletta MT; Fontanini G; Del Tacca M; Danesi R; Falcone A; Bocci G
Pharmacogenomics; 2009 Aug; 10(8):1225-9. PubMed ID: 19663667
[TBL] [Abstract][Full Text] [Related]
12. Bevacizumab combined with two-weekly paclitaxel as first-line therapy for metastatic breast cancer.
Kountourakis P; Doufexis D; Maliou S; Karagiannis A; Kardara E; Margari C; Sykoutri D; Tzovaras A; Ardavanis A
Anticancer Res; 2010 Jul; 30(7):2969-71. PubMed ID: 20683040
[TBL] [Abstract][Full Text] [Related]
13. Fatal hemoptysis in a patient with breast cancer treated with bevacizumab and paclitaxel.
Philippin-Lauridant G; Thureau S; Ouvrier MJ; Blot E
Ann Oncol; 2008 Nov; 19(11):1977-8. PubMed ID: 18801882
[No Abstract] [Full Text] [Related]
14. Modified resistance to chemotherapy and trastuzumab by bevacizumab in locally recurrent breast cancer.
Farhat MH; El-Saghir NS; Shamseddine AI
Breast; 2009 Feb; 18(1):66-8. PubMed ID: 19013064
[TBL] [Abstract][Full Text] [Related]
15. Adverse events in bevacizumab and chemotherapy: patient management.
Blowers E; Hall K
Br J Nurs; 2009 Apr 9-22; 18(7):424-8. PubMed ID: 19373187
[TBL] [Abstract][Full Text] [Related]
16. Bevacizumab and paclitaxel for breast cancer patients with central nervous system metastases: a case series.
Labidi SI; Bachelot T; Ray-Coquard I; Mosbah K; Treilleux I; Fayette J; Favier B; Galy G; Blay JY; Guastalla JP
Clin Breast Cancer; 2009 May; 9(2):118-21. PubMed ID: 19433393
[TBL] [Abstract][Full Text] [Related]
17. Impaired wound healing and bilateral mastectomy flap necrosis in a patient with locally advanced breast cancer after neoadjuvant Paclitaxel with bevacizumab.
Lazzati V; Zygoń J; Lohsiriwat V; Veronesi P; Petit JY
Aesthetic Plast Surg; 2010 Dec; 34(6):796-7. PubMed ID: 20567970
[No Abstract] [Full Text] [Related]
18. First-line bevacizumab in combination with weekly paclitaxel for metastatic breast cancer: efficacy and safety results from a large, open-label, single-arm Japanese study.
Aogi K; Masuda N; Ohno S; Oda T; Iwata H; Kashiwaba M; Fujiwara Y; Kamigaki S; Ito Y; Ueno T; Takashima S
Breast Cancer Res Treat; 2011 Oct; 129(3):829-38. PubMed ID: 21805309
[TBL] [Abstract][Full Text] [Related]
19. Safety of bevacizumab in patients with metastatic breast cancer.
Hamilton EP; Blackwell KL
Oncology; 2011; 80(5-6):314-25. PubMed ID: 21778772
[TBL] [Abstract][Full Text] [Related]
20. The risk of gastrointestinal perforation and/or fistula in patients with recurrent ovarian cancer receiving bevacizumab compared to standard chemotherapy: a retrospective cohort study.
Sfakianos GP; Numnum TM; Halverson CB; Panjeti D; Kendrick JE; Straughn JM
Gynecol Oncol; 2009 Sep; 114(3):424-6. PubMed ID: 19552944
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
